Computer-Aided Screening and Revealing Action Mechanism of Food-Derived Tripeptides Intervention in Acute Colitis

Huifang Ge1,2, Ting Zhang1, Yuanhu Tang1

  • 1Jilin Provincial Key Laboratory of Nutrition and Functional Food, College of Food Science and Engineering, Jilin University, Changchun 130062, China.

Insights

Food-derived tripeptides show potential for treating colitis by modulating key inflammatory and cell signaling pathways. This study used computational methods to identify specific tripeptides and their molecular targets for colitis therapy.

Area of Science:

  • Nutritional biochemistry
  • Computational biology
  • Pharmacology

Background:

  • Colitis symptoms can be alleviated by food-derived tripeptides.
  • The precise mechanisms of tripeptide action in colitis are not well understood.
  • There is a need for novel nutritional compounds for colitis management.

Purpose of the Study:

  • To investigate the therapeutic mechanisms of food-derived tripeptides against acute colitis.
  • To identify potential molecular targets and signaling pathways involved in tripeptide-mediated colitis relief.
  • To screen a large library of tripeptides for their efficacy against colitis using computational approaches.

Main Methods:

  • Utilized a computer-aided screening strategy to evaluate 8000 food-derived tripeptides.
  • Constructed protein-protein and protein-tripeptide networks using PharmMapper and STRING.
  • Identified key signaling pathways (e.g., Ras, PI3K-Akt) via DAVID software.
  • Performed molecular docking of selected tripeptides against major targets (AKT1, EGFR, MMP9) using Autodock.

Main Results:

  • Identified 41 hub targets and 30 significant KEGG pathways related to inflammation and cell regulation in colitis.
  • Discovered 52 tripeptides with significant binding affinities to target proteins AKT1, EGFR, and MMP9.
  • Molecular docking revealed hydrogen-bonding and hydrophobic interactions with binding energies mostly below -7.13 kcal/mol.

Conclusions:

  • Food-derived tripeptides exhibit potential therapeutic mechanisms for colitis.
  • Computational screening effectively identified promising tripeptide candidates and their molecular targets.
  • This study provides a foundation for developing tripeptide-based nutritional therapies for colitis.

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
393
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
223
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
293